Skip to main content
Premium Trial:

Request an Annual Quote

BioNanomatrix Lands $5.1M in Venture Financing

NEW YORK (GenomeWeb News) – DNA analysis firm BioNanomatrix has secured $5.1 million in series A venture financing, lead investor Battelle Ventures said today.
BioNanomatrix is developing nanoscale single-molecule imaging and analytic platforms with applications in genome analysis and clinical diagnostics. 
The funding round included an investment from Battelle’s affiliate Innovation Valley Partners, and from KT Venture Group. Ben Franklin Technology Partners and 21 Ventures also participated in the round through debt conversion agreements.
Battelle said that biotechnology executive Edward Erickson and Battelle partner Tracy Warren have joined BioNanomatrix’ board of directors.
Warren said that the BioNanomatrix technology, which is based on nanochips that are compatible with off-the-shelf optics, can be used to “significantly reduce the time, complexity and cost dynamics of sequencing the genome and carrying out genetic analyses.”
In September, BioNanomatrix and partner Complete Genomics were awarded an $8.8 million grant from the US National Institute of Standards and Technology to develop a high-throughput sequencing technology that they said will be able to sequence a human genome in eight hours for less than $100.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.